IP Library Granted Patent US 10,533,205
Granted Patent B1
US 10,533,205 · App. 14/511,103 · Granted Jan 14, 2020

Kaurenoic acid glycoside precursors and methods of synthesis

Inventor: Brandon Zipp (Davis, CA)
Assignee: Vitality Biopharma, Inc.
C12P19/44A61K31/704A61K31/7028C07H13/08C07H15/18C12P19/56
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,533,205
App. No.
14/511,103
Granted
Jan 14, 2020
Kind
B1
Abstract

Ent-kaurenoic acid glycoside precursor compositions and synthesis methods are provided. The KA-19-monoside, KA-19-bioside and KA-19-trioside precursors can be used as starting materials for a variety of kaurenoic acid based reactions. The precursors provide alternative synthesis pathways for steviol glycosides to the natural pathway based on Steviol biosynthesis. The alternative synthesis pathways using the precursors also circumvent the rate limiting step of the natural Steviol biosynthesis pathway. The precursors can be used individually or in combination to produce a mixture or individual steviol glycosides such as Rebaudioside A, Rebaudioside D or Rebaudioside M. Control over the precursor quantities and composition allows control over the composition of the resulting steviol glycosides that are finally produced.

Claims (14)

1. A kaurenoic-acid-19-monoglycoside having the following structural formula:

wherein the sugar is fructose.

2. A kaurenoic-acid-19-bi-glycoside having the following structural formula:

wherein the sugar is selected from the group consisting of glucose, fructose, xylose and rhamnose, with the proviso that COO-sugar-sugar is other than COO-glucose-glucose.

3. A kaurenoic-acid-19-tri-glycoside having the following structural formula:

wherein the sugar is selected from the group consisting of glucose, fructose, xylose and rhamnose.

4. The compound of claim 2 , wherein the sugar comprises a glucose.

5. The compound of claim 2 , wherein the sugar comprises a fructose.

6. The compound of claim 2 , wherein the sugar comprises a xylose.

7. The compound of claim 2 , wherein the sugar comprises a rhamnose.

8. The compound of claim 3 , wherein the sugar comprises a glucose.

9. The compound of claim 3 , wherein the sugar comprises a fructose.

10. The compound of claim 3 , wherein the sugar comprises a xylose.

11. The compound of claim 3 , wherein the sugar comprises a rhamnose.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2024
From: VITALITY BIOPHARMA, INC.
To: GRAPHIUM BIOSCIENCES, INC.
Reel/Frame 067676/0714 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2016
From: ZIPP, BRANDON
To: STEVIA FIRST CORPORATION
Reel/Frame 040391/0251 →
CHANGE OF NAME Recorded Nov 21, 2016
From: STEVIA FIRST CORPORATION
To: VITALITY BIOPHARMA, INC.
Reel/Frame 040745/0091 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 26, 2014
From: ZIPP, BRANDON
To: STEVIA FIRST CORPORATION
Reel/Frame 034269/0599 →
Continuity (1)
Provisional Application 61888989 · Oct 9, 2013